Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, it is involved in 6 clinical trials, of which 3 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Icovamenib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Icovamenib is expected to reach an annual total of $79 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Biomea Fusion Overview
Biomea Fusion is a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers. The company is headquartered in Palo Alto, California, the US.
The operating loss of the company was US$83.6 million in FY2022, compared to an operating loss of US$41.7 million in FY2021. The net loss of the company was US$81.8 million in FY2022, compared to a net loss of US$41.6 million in FY2021.
For a complete picture of Icovamenib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.